CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Trading 06-05 10:28:06 EDT

0.1654

-0.0086

-4.94%

High0.1702	Low0.1630	Vol549.24K
Open0.1702	D1 Closing0.1740	Amplitude4.14%
Mkt Cap3.19M	Tradable Cap1.73M	Total Shares19.31M
T/O90.95K	T/O Rate5.26%	Tradable Shares10.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":0.1654,"timestamp":1780669588922,"preClose":0.174,"halted":0,"volume":549235,"delay":0,"changeRate":-0.049425287356321825,"floatShares":10433500,"shares":19311600,"eps":-3.962701,"marketStatus":"Trading","change":-0.0086,"latestTime":"06-05 10:28:06 EDT","open":0.1702,"high":0.1702,"low":0.163,"amount":90947.41721609999,"amplitude":0.041379,"askPrice":0.1685,"askSize":500,"bidPrice":0.1652,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-3.962701,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780689600000},"marketStatusCode":2,"adr":0,"exchange":"AMEX","adjPreClose":0.174,"preHourTrading":{"tag":"盘前","latestPrice":0.1674,"preClose":0.174,"latestTime":"09:28 EDT","volume":109981,"amount":18632.743461039998,"timestamp":1780666114811,"change":-0.0066,"changeRate":-0.037931,"amplitude":0.044828},"postHourTrading":{"tag":"盘后","latestPrice":0.1734,"preClose":0.174,"latestTime":"19:51 EDT","volume":119023,"amount":20426.298157,"timestamp":1780617063602,"change":-0.0006,"changeRate":-0.003448,"amplitude":0.022989},"volumeRatio":0.722334},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2639711677","title":"Calidi Biotherapeutics issues amended warrant for 17,391,304 shares at $0.23 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2639711677","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639711677?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:01","pubTimestamp":1780088487,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics issued an amended and restated warrant in a private placement to an accredited investor on May 28, 2026.The warrant covers up to 17,391,304 unvested common shares at an exercise price of $0.23.The minimum vesting acquisition amount increased to $1 million from $500,000.The vesting termination date moved to Sept. 30, 2026 from July 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL8hRRs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638546501","title":"Calidi announces online abstract acceptances at 2026 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638546501","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638546501?lang=en_us&edition=fundamental","pubTime":"2026-05-26 23:37","pubTimestamp":1779809840,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics announced that two abstracts showcasing the Company’s RedTail platform have been accepted for online publication at t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-announces-online-abstract-acceptances-at-2026-asco-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-announces-online-abstract-acceptances-at-2026-asco-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638051457","title":"Calidi Biotherapeutics to present RedTail platform data at ASCO annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638051457","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638051457?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:05","pubTimestamp":1779797140,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics will have two RedTail platform abstracts published online for the 2026 ASCO Annual Meeting, May 29 to June 2, 2026, in Chicago.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLzj1jK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","SG9999014039.USD","BK4139","IE00B3QW5Z07.USD","CLDI","LU2210150020.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","BK4588","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637834750","title":"Calidi provides required NYSE American disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2637834750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637834750?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:05","pubTimestamp":1779487557,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics advised that its Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2025...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-provides-required-nyse-american-disclosure-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-provides-required-nyse-american-disclosure-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NYSE","AFG","BK4107","BK4117","CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637898347","title":"Calidi flags going-concern note in 2025 audit report for NYSE American disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2637898347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637898347?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:00","pubTimestamp":1779487220,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics flagged that its 2025 Form 10-K audit report includes a going-concern explanatory paragraph.The disclosure was issued to meet NYSE American Section 610 requirements.The notice stated it does not reflect any change or amendment to the company’s 2025 filings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLMFxbw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2095319765.USD","IE00B3QW5Z07.USD","CLDI","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014021.USD","BK4139","BK4585","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729347","title":"Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729347","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729347?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:58","pubTimestamp":1778792300,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52583409/calidi-biotherapeutics-q1-eps-0-43-beats-1-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635438726","title":"Calidi Biotherapeutics Q1 net loss narrows 19% to $4.11 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635438726","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635438726?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:42","pubTimestamp":1778791379,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics posted a net loss of $4.11 million for the quarter ended March 31, 2026, narrowing 19% from a year earlier.Operating loss improved 17% to $4.19 million, while total operating expenses fell 17% to $4.19 million.Research and development expense rose 7% to $2.59 million, while general and administrative costs dropped 39% to $1.6 million.Cash totaled $6.6 million at March 31, 2026, and management said it lacks sufficient cash to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gatherin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLb8GdYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725302","title":"Press Release: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725302","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725302?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:10","pubTimestamp":1778789400,"startTime":"0","endTime":"0","summary":"-- Presented new data on CLD-401 at the AACR conference in San Diego, CA,detailing the profound immune changes in the tumor microenvironment. induced by CLD-401; IND filing for CLD-401 expected by end of 2026. detailing the use of the RedTail platform to create in vivo T-cell. engagers that simultaneously express both a T-cell engager and a T-cell. activator at high levels exclusively in the tumor microenvironment;presented new data on CLD-501, a TROP-2 in vivo T-cell engager. -- Demonstrated $1 million reduction in general and administrative expenses. IL15-SA expression may dramatically expand the therapeutic window of. \"We are excited about the continued progress at Calidi,\" said Eric Poma, PhD, Calidi Biotherapeutics CEO. \"We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts. We have also expanded what the RedTail platform can do with our new approach of in situ T-cell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","CLDI","EEV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278450","title":"Calidi Biotherapeutics CSO presents RedTail platform at ASGCT conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278450","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278450?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:04","pubTimestamp":1778673841,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics to present at American Society for Gene and Cell Therapy annual conference in Boston on May 14.Chief Scientific Officer Antonio F. Santidrian scheduled to outline RedTail systemic virotherapy platform, including new data on lead program CLD-401.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8SKMfV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","CLDI","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","NDAQ","SG9999014021.USD","BK4585","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634467463","title":"Calidi issues warrant for up to 17,391,304 shares at $0.23 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634467463","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634467463?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:18","pubTimestamp":1778275097,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics issued an unregistered warrant in a private placement on May 6, 2026 to an accredited investor for up to 17,391,304 shares of common stock at an exercise price of $0.23.Warrant becomes exercisable on Sept. 8, 2026, with vesting tied to any registered common stock purchases by holder of up to $4 million through July 8, 2026.Transaction has no commitment for either side to complete any share issuances tied to the vesting schedule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL3X8gY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631519415","title":"BRIEF-Calidi Biotherapeutics Announces Strategic Partnership With Transferai","url":"https://stock-news.laohu8.com/highlight/detail?id=2631519415","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631519415?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:19","pubTimestamp":1777465171,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Strategic Partnership With Transferai April 29 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH TRANSFER","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUA6HJFSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516027","title":"Calidi Biotherapeutics partners with TransferAI to streamline CLD-401 IND submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516027","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516027?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:08","pubTimestamp":1777464488,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics entered collaboration with TransferAI to streamline IND submission process for CLD-401 using TransferAI agentic AI platform, Sofie.Partnership targets efficiency gains across regulatory workflows supporting Calidi plan to file CLD-401 IND by year end.CLD-401 is Calidi lead RedTail program, a systemically delivered virotherapy engineered to express IL-15 superagonist.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL3vVyr4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","CLDI","NDAQ","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631956516","title":"Calidi Biotherapeutics Announces Strategic Partnership With Transferai to Drive Efficiencies in the Ind Submission Process for Cld-401 Using Agentic AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2631956516","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631956516?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUA6HJFSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516135","title":"Calidi Biotherapeutics Inc - Expects Cld-401 Ind Filing by Year End","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516135?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUA6HJFSH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631553990","title":"Calidi Biotherapeutics publishes RedTail platform presentation on systemic genetic medicine delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2631553990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631553990?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:40","pubTimestamp":1777423219,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics outlined RedTail, a vaccinia-virus platform designed for systemic delivery of genetic medicines with tumor-selective replication.Platform design aims to reduce immune clearance using extracellular enveloped virus production with CD55 overexpression.Calidi identified CLD-401 as lead program, a RedTail vector engineered for tumor-local IL-15 superagonist expression to drive tumor lysis and immune priming.Company expects IND filing for CLD-401 in 2026, targeting a Phase I monotherapy study in relapsed or refractory solid tumors.Calidi also highlighted partnering goals to license RedTail programs defined by tumor marker or genetic payloads, including constructs carrying up to 3 payloads.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5FR4dn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629032074","title":"Calidi presents new data on CLD-401 at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2629032074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629032074?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:29","pubTimestamp":1776778188,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics will present new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-cld-401-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-cld-401-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628472535","title":"Calidi presents new data on in situ t-cell engagers at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2628472535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628472535?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:54","pubTimestamp":1776689678,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics presented new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-in-situ-t-cell-engagers-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-presents-new-data-on-in-situ-t-cell-engagers-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174003","title":"Calidi presents preclinical data for RedTail-derived CLD-401, targets IND filing end-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174003?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:07","pubTimestamp":1776686825,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics presented new preclinical data on April 19, 2026 at AACR on its RedTail platform designed to drive tumor-restricted expression of immune-activating payloads.Results showed RedTail constructs could support simultaneous T-cell activation and in-tumor production of a T-cell engager, an approach aimed at improving activity in solid tumors while limiting peripheral exposure.Calidi highlighted CLD-401 as lead RedTail candidate, positioning it to remodel tumor microenvironment and support localized immune activation.Company also advanced CLD-501, a TROP2-targeting in situ T-cell engager program intended to reduce off-tumor risk tied to that antigen.Calidi expects to file an IND for CLD-401 by end of 2026, setting up a potential clinical entry point for RedTail.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL3b26wS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","CLDI","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2210149790.SGD","NDAQ","LU2210150020.SGD","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798624","title":"Calidi Biotherapeutics publishes RedTail virotherapy platform presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628798624?lang=en_us&edition=fundamental","pubTime":"2026-04-20 01:26","pubTimestamp":1776619587,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics published a research presentation outlining its RedTail dual-programmable virotherapy platform for systemic tumor targeting and localized gene delivery.RedTail uses a tumor-selective replicating extracellular enveloped vaccinia virus engineered with a chimeric CD55 to improve resistance to complement and neutralizing antibodies, supporting IV administration.Program updates highlighted CLD-401, designed for tumor-localized expression of an IL-15 superagonist, with preclinical data showing preferential tumor amplification with low off-tumor signal.Calidi also described CLD-501 as a next-generation construct intended to co-express an IL-15 superagonist with tumor-targeting bispecific T-cell engagers for localized activity in solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL6jKvGd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628782724","title":"Calidi Biotherapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628782724","media":"Reuters","labels":["shareholding","conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628782724?lang=en_us&edition=fundamental","pubTime":"2026-04-18 05:26","pubTimestamp":1776461162,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics scheduled virtual annual shareholder meeting for June 12, 2026.Shareholders set to vote on election of Class III director nominee Scott Leftwich to serve until 2029 annual meeting.Ballot includes auditor ratification for CBIZ CPAs P.C. for fiscal 2026.Investors to consider reverse stock split ratio range of 1-for-2 to 1-for-16.Meeting agenda also includes amendment to 2023 Equity Incentive Plan to raise share authorization to 1,950,000, plus potential adjournment to solicit additional votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLknnXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.0842},{"period":"1month","weight":-0.1792},{"period":"3month","weight":-0.5176},{"period":"6month","weight":-0.8808},{"period":"1year","weight":-0.9602},{"period":"ytd","weight":-0.8513}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.046},{"period":"3month","weight":0.126},{"period":"6month","weight":0.1041},{"period":"1year","weight":0.2704},{"period":"ytd","weight":0.1102}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.185839},{"month":2,"riseRate":0.6,"avgChangeRate":-0.062337},{"month":3,"riseRate":0.4,"avgChangeRate":-0.220856},{"month":4,"riseRate":0.2,"avgChangeRate":-0.161642},{"month":5,"riseRate":0.2,"avgChangeRate":-0.101283},{"month":6,"riseRate":0.6,"avgChangeRate":-0.067704},{"month":7,"riseRate":0.75,"avgChangeRate":0.345315},{"month":8,"riseRate":0.25,"avgChangeRate":-0.291823},{"month":9,"riseRate":0,"avgChangeRate":-0.182897},{"month":10,"riseRate":0.75,"avgChangeRate":-0.07151},{"month":11,"riseRate":0.5,"avgChangeRate":0.188661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.191351}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction